First Trust Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

First Trust Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-36,183	Closed	-$365K	–	381
2022 Q4	$365K	Buy	36,183 +17,806	+97%	+$178K	0.02%	312
2022 Q3	$182K	Hold	18,377	–	–	0.01%	425
2022 Q2	$182K	Hold	18,377	–	–	0.01%	380
2022 Q1	$181K	Sell	18,377 -81,624	-82%	-$804K	0.02%	227
2021 Q4	$984K	Buy	100,001 +10,001	+11%	+$98.2K	0.17%	136
2021 Q3	$877K	Buy	+90,000	New	+$872K	0.13%	155

First Trust Capital Management's BIOT Position: Q1 2023 in Review

First Trust Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 36,183 shares — an estimated $365K sold.

First Trust Capital Management first reported a position in BIOT in Q3 2021 and held it in 6 quarters. The position peaked at $984K in Q4 2021. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

First Trust Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
First Trust Capital Management sold 36,183 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $365K.
First Trust Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q3 2021 and held it in 6 quarters.
First Trust Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $984K in Q4 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on First Trust Capital Management's 13F filing for Q1 2023, filed 12 May 2023.